Estimaciones de analistas de Wall Street para KalVista Pharmaceuticals, Inc. (KALV): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Ratios de valoración
| Precio / Valor contable | -503.31 |
| EV / EBITDA | -12.74 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $1.5M | $8.4M | $16.1M | $12.7M | 0 | 0 | 0 | 0 | 0 | $73.6M |
| Coste de Ventas | $12666 | $18237 | $35021 | $40.2M | $41.3M | 0 | 0 | $86.2M | 0 | $6.1M |
| Beneficio Bruto | $1.5M | $8.4M | $16.1M | -$27.5M | -$41.3M | 0 | 0 | -$86.2M | 0 | $67.5M |
| I+D | $12.7M | $18.2M | $35.0M | $40.2M | $41.3M | $70.2M | $80.3M | $86.2M | $71.7M | $55.6M |
| Generales y Administrativos | $11.2M | $8.9M | $10.9M | $13.0M | $16.6M | $26.4M | $30.6M | $54.3M | $116.3M | $183.7M |
| Gastos Operativos | $23.8M | $27.1M | $45.9M | $13.0M | $16.6M | $96.6M | $110.9M | $54.3M | $188.0M | $239.4M |
| Beneficio Operativo | -$22.3M | -$18.7M | -$29.8M | -$40.5M | -$57.9M | -$96.6M | -$110.9M | -$140.4M | -$188.0M | -$171.8M |
| EBITDA | -$22.3M | -$18.5M | -$29.4M | -$40.0M | -$57.4M | -$80.7M | -$94.4M | -$134.3M | -$173.3M | -$150.6M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.8M | $19.3M |
| Beneficio Antes de Impuestos | -$18.6M | -$15.8M | -$20.7M | -$29.0M | -$46.2M | -$82.3M | -$92.9M | -$135.1M | -$180.1M | -$171.4M |
| Impuestos | 0 | 0 | $124000 | $124000 | 0 | 0 | 0 | -$8.5M | $3.4M | -$7.1M |
| Beneficio Neto | -$18.6M | -$15.8M | -$20.8M | -$29.1M | -$46.2M | -$82.3M | -$92.9M | -$126.6M | -$183.4M | -$164.3M |
| BPA | $-1.92 | $-1.53 | $-1.38 | $-1.64 | $-2.33 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | $-3.23 |
| BPA Diluido | $-1.92 | $-1.53 | $-1.38 | $-1.64 | $-2.33 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | $-3.23 |
| Acciones en Circulación (Diluidas) | $9.7M | $10.3M | $15.1M | $17.7M | $19.1M | $24.5M | $27.9M | $36.8M | $49.7M | $50.9M |
Precio
| Precio | $27.00 |
| Capitalización | $1.4B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explorar sector: Healthcare · Biotechnology
Más secciones de KALV: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones